Altered neurotransmission prior to cognitive decline in AβPP/PS1 mice, a model of Alzheimer's disease

J Alzheimers Dis. 2015;44(3):771-6. doi: 10.3233/JAD-142160.

Abstract

Indirect evidence supports altered glutamate signaling with Alzheimer's disease, however, it is not known if glutamate neurotransmission is impacted prior to cognitive decline. We examined cognition and glutamate neurotransmission in 2-4 month AβPP/PS1, an Alzheimer's disease model, and age-matched control mice. There were no differences in learning and memory as assessed by Morris water maze. However, in vivo electrochemical measures of potassium-evoked glutamate release in the CA1, but not the CA3 or dentate, was significantly elevated in AβPP/PS1 mice. These data support changes in the glutamatergic system that precedes cognitive decline in a mouse model of Alzheimer's disease.

Keywords: Alzheimer's disease; biological markers; cognition; glutamic acid.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / complications*
  • Alzheimer Disease / genetics
  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • Brain / drug effects
  • Brain / metabolism*
  • Cognition Disorders / etiology*
  • Disease Models, Animal
  • Glutamic Acid / metabolism
  • Humans
  • Male
  • Maze Learning / physiology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Potassium Chloride / pharmacology
  • Presenilin-1 / genetics
  • Synaptic Transmission / physiology*

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • PSEN1 protein, human
  • Presenilin-1
  • Glutamic Acid
  • Potassium Chloride